Payment overview · 2025
General Payments
$865.81
40 reported records · 15 companies
Healthcare provider profile · identity verified
Juan C Dominguez, MD
Allopathic & Osteopathic Physicians|Family Medicine · SAINT JOSEPH, MO · NPI 1023036001
Verified facts
What the public records show
CMS Open Payments records show Juan C Dominguez, MD received $865.81 in general payments during 2025 across 40 reported records.
ABBVIE INC. accounted for 28.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $248.89 | 28.8% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $189.46 | 21.9% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $116.79 | 13.5% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $52.72 | 6.1% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $46.82 | 5.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.41 | 4.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.30 | 3.4% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $25.72 | 3.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $24.32 | 2.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.70 | 2.6% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $17.20 | 2.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.79 | 1.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.45 | 1.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.71 | 1.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.53 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $865.81 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $159.56 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $131.97 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $121.78 | 7 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $116.79 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $107.38 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $94.50 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $52.72 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $52.72 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $46.82 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $34.41 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $29.30 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $29.30 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $29.30 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $28.16 | 2 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $25.72 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $24.32 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.70 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | 13 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 446 | 137 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 414 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 378 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 365 | 95 |
| Alprazolam | Alprazolam | 342 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 314 | 98 |
| Lisinopril | Lisinopril | 300 | 85 |
| Omeprazole | Omeprazole | 266 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 260 | 84 |
| Metformin Hcl | Metformin Hcl | 249 | 72 |
| Metoprolol Tartrate | Metoprolol Tartrate | 200 | 54 |
| Potassium Chloride | Potassium Chloride | 197 | 65 |
| Pregabalin | Pregabalin | 194 | 50 |
| Prednisone | Prednisone | 190 | 129 |
| Zolpidem Tartrate | Zolpidem Tartrate | 190 | 48 |
| Azithromycin | Azithromycin | 174 | 122 |
| Tramadol Hcl | Tramadol Hcl | 164 | 65 |
| Lorazepam | Lorazepam | 156 | 32 |
| Meloxicam | Meloxicam | 154 | 49 |
| Citalopram Hbr | Citalopram Hydrobromide | 150 | 41 |
| Furosemide | Furosemide | 147 | 44 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 141 | 41 |
| Gabapentin | Gabapentin | 137 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 130 | 38 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 120 | 39 |
| Clonazepam | Clonazepam | 110 | 27 |
| Losartan Potassium | Losartan Potassium | 103 | 33 |
| Simvastatin | Simvastatin | 103 | 36 |
| Celecoxib | Celecoxib | 96 | 25 |
| Famotidine | Famotidine | 94 | 23 |
| Temazepam | Temazepam | 94 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 84 | 18 |
| Carvedilol | Carvedilol | 81 | 22 |
| Montelukast Sodium | Montelukast Sodium | 80 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 79 | 28 |
| Allopurinol | Allopurinol | 73 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 21 |
| Donepezil Hcl | Donepezil Hcl | 69 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 16 |
| Bupropion Xl | Bupropion Hcl | 64 | 17 |
| Buspirone Hcl | Buspirone Hcl | 61 | 18 |
| Ibandronate Sodium | Ibandronate Sodium | 58 | 22 |
| Fenofibrate | Fenofibrate | 57 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 13 |
| Ozempic | Semaglutide | 54 | 13 |
| Trazodone Hcl | Trazodone Hcl | 52 | 21 |
| Januvia | Sitagliptin Phosphate | 51 | suppressed |
| Ezetimibe | Ezetimibe | 49 | 12 |
| Lovastatin | Lovastatin | 48 | 12 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 47 | 19 |
| Primidone | Primidone | 46 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 46 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Nifedipine Er | Nifedipine | 43 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | 15 |
| Diazepam | Diazepam | 42 | 14 |
| Meclizine Hcl | Meclizine Hcl | 41 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 32 |
| Valsartan | Valsartan | 41 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 37 | 17 |
| Levofloxacin | Levofloxacin | 36 | 27 |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 13 |
| Lamotrigine | Lamotrigine | 35 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 35 | suppressed |
| Baclofen | Baclofen | 34 | suppressed |
| Telmisartan | Telmisartan | 34 | suppressed |
| Ibuprofen | Ibuprofen | 33 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Famciclovir | Famciclovir | 25 | 11 |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 24 | 24 |
| Colchicine | Colchicine | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | 12 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Nystatin | Nystatin | 22 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 19 |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 14 |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Eliquis | Apixaban | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $865.81 · 40 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, COMIRNATY, CREON, FARXIGA, FREESTYLE LIBRE 3, IBSRELA, INJECTAFER, JARDIANCE, JOURNAVX, LINZESS, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, REXULTI, UBRELVY, VRAYLAR, Veozah, WATCHMAN FLX, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error